BrainStorm reports new survival data from EAP for NurOwn
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 16 2025
0mins
Should l Buy ?
Survival Data from NurOwn Treatment: BrainStorm Cell Therapeutics reported that 90% of participants in their Expanded Access Program for NurOwn, who had amyotrophic lateral sclerosis (ALS), survived more than five years from symptom onset, significantly higher than the typical 10% survival rate. The median survival observed was 6.8 years.
Implications for Future Trials: The encouraging survival outcomes suggest that the benefits of NurOwn treatment are not due to chance, supporting the upcoming Phase 3b clinical trial under FDA Special Protocol Assessment to further investigate its effectiveness for ALS patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
